Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash

Nanobiotix has tweaked the terms of a licensing deal with Johnson & Johnson over the French biotech’s phase 3-stage cancer drug in order to keep the cash flowing through to next year.